Navigation Links
Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
Date:9/2/2008

SOUTH SAN FRANCISCO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced that it will hold a conference call and webcast on Wednesday, September 3, 2008 at 11:30 am Eastern time (8:30 am Pacific time). During the call, Anesiva management will update its corporate strategy and product development milestones, following a comprehensive review of the company's business.

Interested parties can listen to the live conference call by dialing 866-616-3642 (international dial: 706-643-3817) or by logging on to http://www.anesiva.com and going to the Investor Information page. For those unable to participate via the Internet, a replay will be available for seven days after the call by dialing 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 62641912. The webcast will be available until the company's next quarterly financial results conference call.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a commercial-stage specialty pharmaceutical company that seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. For full Zingo prescribing information and other information, visit http://www.zingo.com. An application is under FDA review to expand the Zingo label indication to include adults.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in multiple clinical trials for the management of acute pain following orthopedic surgeries. Adlea has been shown in Phase 2 trials to reduce pain after only a single administration for weeks to months in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development and commercialization of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer
2. Anesiva to Present at BioCentury Newsmakers Conference on September 4, 2008
3. Anesiva Announces Second Quarter 2008 Financial Results and Update
4. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
5. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
6. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
7. Anesiva Announces First Quarter 2008 Financial Results
8. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
9. Anesiva Announces Expansion of Zingo Agreement in Europe
10. Anesiva Announces New Zingo Marketing and Distribution Agreement
11. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... announced the three Winners and six Finalists of the 2017 Blavatnik Regional Awards ... the Blavatnik Family Foundation and administered by the New York Academy of Sciences ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract ... to improve patient outcomes and quality of life, will now be offering its ... attributed to new regulatory requirements for all new drug products, including the finalization ...
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
Breaking Biology Technology:
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):